Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: NKTR-118 Clear all
Terminated Phase 2 Interventional

Movantik for Opioid-Related Esophageal Disorders

NCT02998606
View directory record Official record
Conditions
Opioid-Induced Disorders, Esophagus Disorder
Interventions
Naloxegol, Placebo Oral Capsule
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415
View directory record Official record
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions
NKTR-118, moxifloxacin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01309841
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 4 Interventional Results available

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

NCT03523520
View directory record Official record
Conditions
Constipation Drug Induced
Interventions
Methylnaltrexone Bromide 150 mg Oral Tablet, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 3, 2026, 7:05 PM EDT
Terminated Phase 4 Interventional Results available

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

NCT02839889
View directory record Official record
Conditions
Cancer, Constipation, Pain
Interventions
Naloxegol, Placebo
Drug
Lead sponsor
Hospice of Henderson County, Inc.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
New York, New York • Flat Rock, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 3, 2026, 7:05 PM EDT
Withdrawn Phase 2 Interventional

Naloxegol for Opioid-Related Gastroparesis

NCT03036891
View directory record Official record
Conditions
Gastroparesis, Opioid Use
Interventions
Naloxegol 25 MG Oral Tablet [Movantik], Placebo Oral Tablet
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 84 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 4 Interventional Results available

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

NCT03060512
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
Polyethylene Glycol 3350, Movantik
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
53
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

NCT01365000
View directory record Official record
Conditions
Healthy
Interventions
NKTR118 Formulation 1, NKTR118 Formulation 2, NKTR118 Formulation 3, NKTR118 Formulation 1a, NKTR118 Formulation 3a
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects

NCT02737059
View directory record Official record
Conditions
Constipation Drug Induced
Interventions
Naloxegol, Codeine, codeine placebo, naloxegol placebo
Drug
Lead sponsor
Michael Camilleri
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 4 Interventional Results available

Ancillary Effects of Oral Naloxegol (Movantik)

NCT03235739
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naloxegol 25 MG, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

NCT01372826
View directory record Official record
Conditions
Renal Impairment
Interventions
NKTR118 Group1, NKTR118 Group 2, NKTR118 Group3, NKTR118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Anaheim, California • Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

NCT00600119
View directory record Official record
Conditions
Opioid Induced Constipation (OIC)
Interventions
placebo, NKTR-118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Huntsville, Alabama • Pinson, Alabama • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol

NCT01594619
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
Naloxegol, Diltiazem XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 3, 2026, 7:05 PM EDT
Terminated Phase 2 Interventional Results available

Naloxegol in Cancer Opioid-Induced Constipation

NCT02745353
View directory record Official record
Conditions
Constipation
Interventions
naloxegol
Drug
Lead sponsor
Joseph Ma
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 3, 2026, 7:05 PM EDT
Terminated Phase 4 Interventional Results available

Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients

NCT02946580
View directory record Official record
Conditions
Constipation
Interventions
MOVANTIK™ (naloxegol), Sugar Pill
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 3, 2026, 7:05 PM EDT
Withdrawn Phase 3 Interventional

The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit

NCT02705378
View directory record Official record
Conditions
Constipation, Critical Illness
Interventions
Polyethylene glycol, naloxegol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 3, 2026, 7:05 PM EDT
Terminated Phase 2 Interventional Results available

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT03087708
View directory record Official record
Conditions
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Naloxegol, Placebo, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
660
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 407 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01395524
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
90
States / cities
Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function

NCT01392807
View directory record Official record
Conditions
Hepatic; Functional Disturbance
Interventions
NKTR-118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01336205
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Usual care
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
169
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118

NCT01533155
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
Nektar 118, Quinidine, Quinidine placebo, Morphine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 3, 2026, 7:05 PM EDT
Terminated Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain

NCT01384292
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
81
States / cities
Huntsville, Alabama • Casa Grande, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 3, 2026, 7:05 PM EDT
Not listed Phase 2Phase 3 Interventional

Naloxegol and Opioid-induced Constipation

NCT03316859
View directory record Official record
Conditions
Constipation, Constipation Drug Induced
Interventions
Naloxegol 25 MG, Placebo pill
Drug · Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 3, 2026, 7:05 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01323790
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
68
States / cities
Mobile, Alabama • Pell City, Alabama • Mesa, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 3, 2026, 7:05 PM EDT